New Scripps Florida Compound Succefully Targets Hard-to-Treat Breast Cancer

New Scripps Florida Compound Successfully Targets Hard-to-Treat Breast Cancer JUPITER, FL, December 16, 2015 Findings from a new study led by scientists from the Florida campus of The Scripps Research Institute (TSRI) suggest a potent new therapeutic approach for a number of hard-to-treat breast cancers.

The study points to an enzyme called casein kinase 1 (CK1 ), a critical regulator of growth, as a novel and highly vulnerable therapeutic target. Increased CK1 expression is common to breast cancer, including the difficult-to-treat subtype called triple negative breast cancer (those cancers not driven by estrogen, progesterone, or the HER-2/neu gene), affecting 10 to 20 percent of breast cancer patients.

The study, which was published today in the journal Science Translational Medicine, was a collaboration among the Florida labs of Derek Duckett and William R. Roush, both of TSRI, and John Cleveland, formerly of TSRI and currently at the Moffitt Cancer Center.

Our findings confirm that aberrant CK1 regulation promotes tumor growth in breast cancers by activating the protein -catenin, said Duckett, an associate professor at Scripps Florida. The best news, however, is that we have been able to treat CK1 -expressing breast cancers with a highly selective and potent CK1 inhibitor developed by Bill Roush's lab that triggers rapid tumor cell death.

At the beginning of the study, the team knew that the -catenin protein was an oncogene in many cancers, but it was unclear why it was activated in these breast cancer types since they lacked typical mutations in those pathways. The researchers suspected the link could be overexpression of CK1 . Their experiments showed that indeed to be the case.

To confirm the new target, the study used the Roush lab compound, called SR-3029. SR-3029 was remarkably successful at blocking the growth of tumors in both animal models and in studies with tumor tissue from breast cancer patients.

SR-3029 removes -catenin from cancer cells, killing the tumors, explained Duckett. This is an extraordinarily promising strategy for targeted treatment with SR-3029, especially in breast cancers that lack targeted treatment options.

These results are just the tip of the iceberg, added Roush, who is professor, associate dean and executive director of medicinal chemistry at TSRI. Inhibitors such as SR-3029 are being studied in a host of different cancers, and we are hopeful this platform can be translated into clinical applications.

The first author of the study, Therapeutic Targeting of Casein Kinase 1 in Breast Cancer, is Laura H. Rosenberg, a TSRI research associate at the time of the study. In addition to Rosenberg, Duckett, Roush and Cleveland, other authors include Marie Lafitte, Victor Quereda, Wayne Grant, Weimin Chen, Mathieu Bibian, Yoshihiko Noguchi and Mohammad Fallahi of TSRI; Chunying Yang of Moffitt Cancer Center and Research Institute; and Jenny C. Chang of Houston Methodist Hospital.

This work was supported in part by the National Institutes of Health (grants CA175094, U54MH074404, P30-CA076292), Rendina Family Foundation, Shear Family Foundation, ThinkPink Kids Foundation, the State of Florida and Moffitt Cancer Center & Research Institute.

About The Scripps Research Institute

The Scripps Research Institute (TSRI) is one of the worlds largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs about 2,700 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists including two Nobel laureates work toward their next discoveries. The institutes graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see www.scripps.edu.

# # #

For information:

Office of Communications

Tel: 858-784-2666

Fax: 858-784-8136

press@scripps.edu

LINK:	http://www.scripps.edu/news/press/2015/20151216duckett.html...
	See more stories from scripps

Most recent headlines